Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate

Journal of Urology

Volumn 163, Issue 4, 2000, Pages 1161-1165

  Ischia, Rudolf ^b   Hobisch, Alfred ^b   Bauer, Richard ^b   Weiss, Ulrike ^b   Gasser, Rudolf W ^b   Horninger, Wolfgang ^b   Bartsch Jr , Georg ^b   Fuchs, Dietmar ^b   Bartsch, Georg ^b   Winkler, Hans ^b   Klocker, Helmut ^b   Fischer Colbrie, Reiner ^b   Culig, Zoran ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Chromogranins; Neuroendocrinology; Prostate; Prostatic neoplasms

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CHROMOGRANIN A; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; SECRETONEURIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 0034066314     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67714-2     Document Type: Article

References (23)

1. Fischer-Colbrie, R., Laslop, A. and Kirchmair, R.: Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol, 46: 49, 1995
2. Ischia, R., Culig, Z., Eder, U. et al: Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line. Prostate, suppl., 8: 80, 1998
3. di Sant' Agnese, P. A.: Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate, suppl., 8: 74, 1998
4. Krijnen, J. L., Janssen, P. J., Ruizeveld de Winter, J. A. et al: Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry, 100: 393, 1993
5. Kadmon, D., Thompson, T. C., Lynch, G. R. et al: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol, 146: 358, 1991
6. Cussenot, O., Villette, J. M., Valeri, A. et al: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol, 155: 1340, 1996
7. Deftos, L. J., Nakada, S., Burton, D. W. et al: Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology, 48: 58, 1996
8. Angelsen, A., Syversen, U., Haugen, O. A. et al: Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate, 30: 1, 1997
9. Kimura, N., Hoshi, S., Takahashi, M. et al: Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol, 157: 565, 1997
10. Wu, J. T., Astill, M. E., Liu, G. H. et al: Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal, 12: 20, 1998
11. Tarle, M. and Rados, N.: Investigation on serum neuron-specific enolase in prostatic cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate, 19: 23, 1991
12. Leitner, B., Fischer-Colbrie, R., Scherzer, G. et al: Secretogranin II: relative amounts and processing to secretoneurin in various rat tissues. J Neurochem, 66: 1312, 1996
13. Kirchmair, R., Hogue-Angeletti, R., Gutierrez, J. et al: Secretoneurin - a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience, 53: 359, 1993
14. Ischia, R., Gasser, R. W., Fischer-Colbrie, R. et al: Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab, 85: 355, 2000
15. Twillie, D. A., Eisenberger, M. A., Carducci, M. A. et al: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542, 1995
16. Hoosein, N., Abdul, M., McCabe, R. et al: Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol, 1: 246, 1995
17. Sehgal, I., Powers, S., Huntley, B. et al: Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA, 91: 4673, 1994
18. Noordzij, M. A., van Weerden, W. M., de Ridder, C. M. et al: Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol, 149: 859, 1996
19. Jongsma, J., Oomen, M. H., Noordzij, M. A. et al: Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol, 154: 543, 1999
20. Pruneri, G., Galli, S., Rossi, R. S. et al: Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate, 34: 113, 1998
21. 125I-secretoneurin analogue to a human monocytic cell line. J Neuroimmunol, 86: 87, 1998
22. Shah, G. V., Rayford, W., Noble, M. J. et al: Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and cytoplasmid Ca2+ transients. Endocrinology, 134: 596, 1994
23. Gkonos, P. J., Ashby, M. H. and Andrade, A. A.: Vasoactive intestinal peptide stimulates prostate-specific antigen secre-tion by LNCaP prostate cancer cells. Regul Pept, 65: 153, 1996